Cargando…
Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3
BACKGROUND: Previous trials have often defined genotype 2 and 3 patients as an “easy to treat” group and guidelines recommend similar management. AIMS: The present study looks for differences between the two genotypes and analyzes predictive factors for SVR. METHODS: Prospective, community-based coh...
Autores principales: | Niederau, Claus, Mauss, Stefan, Schober, Andreas, Stoehr, Albrecht, Zimmermann, Tim, Waizmann, Michael, Moog, Gero, Pape, Stefan, Weber, Bernd, Isernhagen, Konrad, Sandow, Petra, Bokemeyer, Bernd, Alshuth, Ulrich, Steffens, Hermann, Hüppe, Dietrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169557/ https://www.ncbi.nlm.nih.gov/pubmed/25238535 http://dx.doi.org/10.1371/journal.pone.0107592 |
Ejemplares similares
-
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
por: Hofmann, Wolf Peter, et al.
Publicado: (2015) -
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007) -
Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012) -
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015) -
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)